Brind.

Guardant Health reported results from Palo Alto on July 31, 2025. Shield MCD received Breakthrough Device Designation from the FDA and was included in NCCN colorectal cancer screening guidelines.

4 reports, 3 independent Updated Jul 30
Gone quiet
Reports
4
Developments
5
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

Guardant Health reported results from Palo Alto on July 31, 2025. Shield MCD received Breakthrough Device Designation from the FDA and was included in NCCN colorectal cancer screening guidelines.

Who's involved

What this event is mainly about
Guardant HealthFDANational Comprehensive Cancer Network

How it developed

Newest first. Tap a step to see who reported it.
  1. The company Guardant Health, which has a director, is based in Palo Alto.Sub-event
  2. Guardant Health appoints new CFO while Medicare sets pricing for its diagnostic tests.1 source
  3. Guardant Health announced on July 15, 2025, that its test was being used in the NCI's Vanguard Study, with data presented at ASCO in Chicago and FDA review initiated for IDE.Sub-event
  4. Guardant Health announced a partnership on July 30, 2025, aimed at raising awareness about Colorectal Cancer (CRC) screening.Sub-event
  5. Guardant Health's Shield MCD received Breakthrough Device Designation from the FDA and was included in NCCN colorectal cancer screening guidelines.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • dailypolitical.com
  • yahoo.com
  • Business WireGuardant Health Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Revenue growth of 31% broadly driven by strong performance across Oncology, Screening, and Biopharma
  • Unknown outlet